论文信息 - Nilotinib (Tasigna®) and Low Intensity Chemotherapy for First-Line Treatment of Elderly Patients with BCR-ABL1-Positive Acute Lymphoblastic Leukemia: Final Results of a Prospective Multicenter Trial (EWALL-PH02) - 字舞流文

Nilotinib (Tasigna®) and Low Intensity Chemotherapy for First-Line Treatment of Elderly Patients with BCR-ABL1-Positive Acute Lymphoblastic Leukemia: Final Results of a Prospective Multicenter Trial (EWALL-PH02)

J. Cayuela | H. Dombret | K. Spiekermann | S. Leprêtre | P. Chevallier | P. Rousselot | J. Ribera | O. Ottmann | D. Hoelzer | A. Reichle | E. Raffoux | H. Pfeifer | L. Sanhes | W. Jung | A. Viardot | J. Cahn | S. Maury | F. Huguet | P. Turlure | J. Beck | N. Goekbuget | F. Isnard | C. Himberlin | K. Wendelin | M. Escoffre-barbe